![]() |
市場調查報告書
商品編碼
2083406
術中磁振造影市場:依系統類型、技術類型、磁體技術、磁場強度、掃描器類型、應用和最終用戶分類-2026-2032年全球市場預測Intraoperative MRI Market by System Type, Technology Type, Magnet Technology, Field Strength, Scanner Type, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,術中 MRI 市場將成長至 48 億美元,複合年成長率為 12.62%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 20.9億美元 |
| 預計年份:2026年 | 23.2億美元 |
| 預測年份 2032 | 48億美元 |
| 複合年成長率 (%) | 12.62% |
術中磁振造影(iMRI)正逐漸成為醫院和手術中心進行複雜神經外科、脊椎外科以及某些腫瘤手術的策略性技術。透過在手術過程中進行磁振造影,iMRI有助於即時評估腫瘤切除情況、腦移位、解剖結構錯位、手術併發症以及傷口縫合前是否需要即時進行手術調整。
對於醫療服務提供者而言,術中磁振造影市場正受到臨床趨勢的影響,這些趨勢包括最大限度地安全切除、精準導航手術、混合手術室以及手術流程的顯著改進。需求量最大的是三級醫院、大學附屬醫院和癌症研究機構,這些機構的神經外科病例數、多學科專業知識、磁振造影安全管理系統以及投資能力都在推動其應用。
術中磁振造影(iMRI)的格局正在從孤立、昂貴的設備向整合的手術生態系統轉變,該生態系統融合了成像、導航、機器人、麻醉基礎設施、MRI兼容器械和數位化工作流程工具。醫院越來越重視iMRI,不僅將其視為獨立的掃描儀,更將其視為一個能夠改善術中決策、減少不確定性並支持多學科診療的平台。
人工智慧 (AI) 正透過加快影像重建速度、自動分割、決策支援、影像抗蝕劑和最佳化工作流程,逐步影響術中磁振造影 (MRI)。在分秒必爭的手術環境中,AI 驅動的重建和影像解讀有助於減少延誤,同時提供殘餘病灶、水腫、出血和解剖移位的清晰可視化影像。
北美憑藉其先進的醫院基礎設施、高水準的神經外科技術、高場強成像系統的普及以及完善的複雜手術保險報銷體系,仍然是術中磁振造影(MRI)應用主導。尤其在美國,大學醫院和腫瘤醫院持續投資於混合手術室、影像導引神經外科手術以及MRI輔助的手術流程,發揮舉足輕重的作用。同時,加拿大的MRI應用情況則受到省級採購、集中式三級醫療服務以及實證醫學技術評估的影響。
在歐盟內部,研究型醫院、跨境臨床合作、規範化的採購以及對實證醫學在先進外科影像技術應用方面的高度重視,正在推動術中磁振造影(MRI)的需求。七國集團(G7)憑藉其先進的外科基礎設施、高額的醫療費用支出、完善的臨床培訓體系和強大的神經外科學術網路,為高階影像系統的發展奠定了成熟的基礎。北約成員國與高所得的醫療體系高度重合,因此對強大的醫院基礎設施、先進的創傷護理以及支持複雜顱腦和脊椎手術的神經外科能力提出了更高的要求。
美國正引領術中磁振造影(iMRI)的商業化進程,其主要管道包括大學醫院、綜合醫療網路和專科癌症中心,並依托先進的神經外科實踐和積極推廣的影像導引手術。在加拿大,省級醫院系統和三級醫療網路已開始有針對性地部署iMRI;墨西哥和巴西則已發現私立醫院和處理複雜腫瘤及神經外科病例的大型公立轉診機構對iMRI的需求。在歐洲,英國、德國、法國、義大利和西班牙正透過先進的神經外科中心、大學醫院以及國家醫療體系的採購來支持術中磁振造影的應用;而在俄羅斯,iMRI的應用則高度依賴於集中採購、對區域醫療保健的投資以及配備專業的磁振造影和手術團隊。
醫院經營團隊在著手建設術中磁振造影基礎設施之前,應先評估病例數和臨床結果。在最具說服力的商業案例中,神經外科、神經放射科、麻醉科、腫瘤科、手術室管理、設施規劃、生物醫學工程、感染控制和財務等部門通常會基於通用的營運模式開展合作。
本執行摘要是在對經核實的二手資料進行系統性回顧後檢驗的,這些資料包括同行評審的神經外科文獻、醫學影像指南、監管資訊、醫院採購趨勢、產品資料、公共醫療基礎設施數據以及與術中磁振造影和影像導引手術相關的臨床實踐出版物。研究結果從與術中磁振造影市場相關的臨床、技術、區域和營運角度進行了解讀。
術中磁振造影市場正朝著人工智慧驅動的整合式手術影像環境轉型,以支援精準性、安全性和即時決策。儘管資本投資成本、磁振造影安全要求、安裝複雜性以及對術室工作流程的干擾仍然是阻礙因素,但術中可視化的臨床價值在專注於先進神經外科、脊椎外科和腫瘤科的專科醫院中正變得日益重要。
The Intraoperative MRI Market is projected to grow by USD 4.80 billion at a CAGR of 12.62% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.09 billion |
| Estimated Year [2026] | USD 2.32 billion |
| Forecast Year [2032] | USD 4.80 billion |
| CAGR (%) | 12.62% |
Intraoperative MRI (iMRI) is becoming a strategic capability for hospitals and surgical centers that manage complex neurosurgery, spine surgery, and select oncologic procedures. By enabling magnetic resonance imaging during an operation, iMRI supports real-time assessment of tumor resection, brain shift, anatomy displacement, surgical complications, and the need for immediate surgical adjustment before wound closure.
For healthcare providers, the intraoperative MRI market is shaped by the clinical push toward maximal safe resection, precision-guided surgery, hybrid operating rooms, and measurable improvements in surgical workflow. Demand is strongest in tertiary care hospitals, academic medical centers, and cancer institutes where neurosurgical case volume, multidisciplinary expertise, MRI safety governance, and capital investment capacity support adoption.
The iMRI landscape is shifting from isolated high-capital installations toward integrated surgical ecosystems that combine imaging, navigation, robotics, anesthesia infrastructure, MRI-compatible instruments, and digital workflow tools. Hospitals are increasingly evaluating iMRI not as a standalone scanner, but as a platform that can improve intraoperative decision-making, reduce uncertainty, and support multidisciplinary care.
Technology decisions are also moving toward flexible room designs, improved magnet mobility, advanced coils, faster sequences, low-field and high-field configuration choices, and compatibility with surgical navigation platforms. These shifts are significant because operating room time, infection control, staff training, MRI safety zoning, and imaging throughput remain central factors in the return on investment for iMRI-enabled programs.
Artificial intelligence is beginning to influence intraoperative MRI through faster image reconstruction, automated segmentation, decision support, image registration, and workflow orchestration. In surgical environments where timing is critical, AI-assisted reconstruction and interpretation can help reduce delays while supporting consistent visualization of residual lesions, edema, bleeding, and anatomy displacement.
The cumulative impact of AI is expected to be operational as much as clinical. Hospitals can use AI to standardize imaging protocols, support quality assurance, improve surgical planning, and generate structured data for outcomes research. However, deployment must align with regulatory requirements, cybersecurity standards, clinical validation, data governance, and clear accountability between surgeons, radiologists, anesthesiology teams, and technology teams.
North America remains a leading region for intraoperative MRI adoption due to advanced hospital infrastructure, strong neurosurgical specialization, access to high-field imaging systems, and established reimbursement pathways for complex surgical care. The United States is particularly influential because academic medical centers and cancer hospitals continue to invest in hybrid operating rooms, image-guided neurosurgery, and MRI-compatible surgical workflows, while Canada's adoption is shaped by provincial procurement, centralized tertiary care, and evidence-based health technology assessment.
Europe demonstrates steady demand through university hospitals, public health systems, and specialized oncology and neurosurgery networks, with adoption shaped by procurement cycles, medical device regulation, and technology assessment frameworks. Asia-Pacific is gaining momentum as China, Japan, South Korea, India, Australia, and ASEAN countries expand advanced surgical capacity, though adoption varies widely by hospital tier, urban concentration, clinical training depth, and funding model. Latin America shows selective uptake led by Brazil, Mexico, and advanced private hospital networks, while the Middle East is supported by tertiary care investment in GCC countries and national specialty hospital programs. Africa remains at an earlier stage, with deployment concentrated in major urban referral centers where MRI infrastructure, specialist workforce availability, and capital budgeting determine feasibility.
Within the European Union, intraoperative MRI demand is supported by research hospitals, cross-border clinical collaboration, regulated procurement, and a strong emphasis on evidence-based adoption of advanced surgical imaging. G7 markets provide a mature base for premium imaging systems because of advanced surgical infrastructure, high healthcare spending, established clinical training pathways, and strong academic neurosurgery networks. NATO countries overlap significantly with high-income healthcare systems, creating demand for resilient hospital infrastructure, advanced trauma care, and neurosurgical capabilities that can support complex cranial and spine procedures.
BRICS markets are increasingly important as China, India, and Brazil invest in high-acuity healthcare, oncology centers, and neurosurgical capacity, while Russia and South Africa show more selective adoption tied to public procurement priorities and major referral institutions. ASEAN adoption is concentrated in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, with stronger momentum in countries that combine private hospital growth, medical tourism, and specialist training. GCC markets, particularly Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait, are investing in tertiary care hospitals and specialty centers, making the region a strategic opportunity for integrated iMRI suites, MRI safety programs, clinical training, and long-term service models.
The United States leads iMRI commercialization through academic hospitals, integrated delivery networks, and specialty cancer centers, supported by advanced neurosurgical practice and strong adoption of image-guided surgery. Canada shows targeted adoption within provincial hospital systems and tertiary care networks, while Mexico and Brazil demonstrate demand from private hospitals and leading public referral institutions that serve complex oncology and neurosurgery cases. In Europe, the United Kingdom, Germany, France, Italy, and Spain support intraoperative MRI through advanced neurosurgical centers, university hospitals, and national health system procurement, while Russia's adoption is more dependent on centralized purchasing, regional healthcare investment, and availability of specialized MRI and surgical teams.
China is expanding advanced imaging capacity rapidly, with iMRI potential tied to major urban hospitals, oncology centers, and government support for high-end medical technology infrastructure. India's opportunity is concentrated in metropolitan multispecialty hospitals where neurosurgical volume, private investment, and demand for advanced cancer care are rising. Japan and South Korea show strong alignment with precision surgery, advanced medical technology adoption, and highly specialized hospital networks, while Australia benefits from tertiary hospital systems, established neurosurgical expertise, and structured clinical governance for advanced imaging. Across these countries, successful deployment depends on MRI-compatible operating room design, trained multidisciplinary teams, service reliability, and clear evidence linking iMRI use to surgical decision-making and patient outcomes.
Hospital leaders should begin with a case-volume and clinical outcomes assessment before committing to intraoperative MRI infrastructure. The strongest business cases typically align neurosurgery, neuroradiology, anesthesia, oncology, operating room management, facilities planning, biomedical engineering, infection control, and finance around a shared operating model.
Providers should prioritize workflow simulation, staff credentialing, MRI safety governance, service uptime guarantees, emergency protocols, and integration with navigation, robotics, picture archiving, and electronic health record systems. Executives should also develop an evidence plan that tracks extent of resection, reoperation avoidance, procedure time, length of stay, complications, readmissions, and patient outcomes to support long-term value measurement.
This executive summary is developed from a structured review of verified secondary sources, including peer-reviewed neurosurgical literature, medical imaging guidelines, regulatory information, hospital procurement trends, product documentation, public healthcare infrastructure data, and clinical practice publications related to intraoperative MRI and image-guided surgery. Insights are interpreted through clinical, technological, regional, and operational lenses relevant to the iMRI market.
The methodology emphasizes triangulation rather than reliance on a single source. Clinical evidence, technology adoption signals, regional healthcare investment patterns, regulatory considerations, hospital infrastructure indicators, and expert market observations are compared to identify durable trends while avoiding unverified claims, company-specific claims, unsupported market estimates, market sizing, market share analysis, or market forecasting.
The intraoperative MRI market is moving toward integrated, AI-enabled surgical imaging environments that support precision, safety, and real-time decision-making. While capital cost, MRI safety requirements, installation complexity, and operating room workflow disruption remain barriers, the clinical value of intraoperative visualization is increasingly relevant for high-acuity hospitals focused on advanced neurosurgery, spine surgery, and oncology.
Organizations that align iMRI investment with measurable clinical outcomes, digital integration, multidisciplinary execution, and sustainable service models will be better positioned to capture long-term value. As AI, hybrid operating room design, and image-guided surgery mature, iMRI is expected to remain a differentiated capability in premium surgical care and a critical enabler of precision intervention.